Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Benefits of BGF Triple Fixed-Dose Therapy Consistent in COPD Patients Without Exacerbation History

Key clinical point: In patients without a recent exacerbation history, budesonide/glycopyrrolate/formoterol fumarate metered-dose inhaler improved lung function and exacerbations versus dual therapy in patients with moderate to very severe chronic obstructive pulmonary disorder.

Major finding: Treatment with a budesonide/glycopyrrolate/formoterol fumarate metered-dose inhaler significantly reduced the rate of moderate or severe exacerbations, compared with glycopyrrolate/formoterol fumarate (treatment incidence rate ratio, 0.52; 95% confidence interval, 0.37-0.72; P = .0001).

Study details: A subset analysis including 1,411 patients with moderate to severe chronic obstructive pulmonary disorder in the KRONOS study with no exacerbations in the past year.

Disclosures: Dr. Martinez reported disclosures related to AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Chiesi, Sunovion, and Teva.

Citation:

Martinez FJ et al. CHEST 2019, Abstract, doi.org/10.1016/j.chest.2019.08.309